90-Days mortality rate in patients treated within the context of a phase-I trial : How should we identify patients who should not go on trial?ARKENAU, Hendrik-Tobias; OLMOS, David; JOO ERN ANG et al.European journal of cancer (1990). 2008, Vol 44, Num 11, pp 1536-1540, issn 0959-8049, 5 p.Article

Presentation and subsequent publication rates of phase I oncology clinical trialsCAMACHO, Luis H; BACIK, Jennifer; CHEUNG, Alexander et al.Cancer. 2005, Vol 104, Num 7, pp 1497-1504, issn 0008-543X, 8 p.Article

The best guess approach to phase I trial designROSA, Daniela D; HARRIS, John; JAYSON, Gordon C et al.Journal of clinical oncology. 2006, Vol 24, Num 1, pp 206-208, issn 0732-183X, 3 p.Article

TCNU: a ray of hope for designer nitrosoureas?WORKMAN, P.European journal of cancer & clinical oncology. 1987, Vol 23, Num 12, pp 1823-1828, issn 0277-5379Article

Phase I trial of teroxironeNEIDHART, J. A; DEROCHER, D; GREVER, M. R et al.Cancer treatment reports. 1984, Vol 68, Num 9, pp 1115-1119, issn 0361-5960Article

Clinical outcome and prognostic factors for patients treated within the context of a phase I study : the Royal Marsden Hospital experienceARKENAU, H-T; OLMOS, D; ANG, J. E et al.British journal of cancer. 2008, Vol 98, Num 6, pp 1029-1033, issn 0007-0920, 5 p.Article

A phase I clinical tolerance study of rDNA alpha₂ human interferon in patients with non-reticuloendothelial system malignancies = Etude clinique phase I de la tolérance de l'interféron leucocytaire humain alpha 2 recombinant chez les sujets ayant une affection maligne réticulo-endothélialeEDELSTEIN, M. B; SCHELLEKENS, H; LAURENT, T et al.European journal of cancer & clinical oncology. 1983, Vol 19, Num 7, pp 891-894, issn 0277-5379Article

Phase I study of a new anthraquinone derivative, mitoxantrone = Etude phase I d'une nouvelle anthraquinone, la mitoxantroneOGAWA, M; SAITO, T; WAKUI, A et al.Monograph series of the European Organization for Research on Treatment of Cancer. 1983, Vol 12, pp 85-91, issn 0146-0447Article

Multi-Institutional Phase I Trials of Anticancer AgentsDOWLATI, Afshin; MANDA, Sudhir; GIBBONS, Joseph et al.Journal of clinical oncology. 2008, Vol 26, Num 12, pp 1926-1931, issn 0732-183X, 6 p.Article

What Oncologists Believe They Said and What Patients Believe They Heard: An Analysis of Phase I Trial DiscussionsJENKINS, Valerie; SOLIS-TRAPALA, Ivonne; LANGRIDGE, Carolyn et al.Journal of clinical oncology. 2011, Vol 29, Num 1, pp 61-68, issn 0732-183X, 8 p.Article

Translation of innovative designs into phase I trialsROGATKO, André; SCHOENECK, David; JONAS, William et al.Journal of clinical oncology. 2007, Vol 25, Num 31, pp 4982-4986, issn 0732-183X, 5 p.Article

PENTAMETHYLMELAMINE (PMM): PHASE I CLINICAL AND PHARMACOKINETIC STUDIES = PENTAMETHYLMELAMINE: ETUDE CLINIQUE PHASE I ET PHARMACOCINETIQUEMUINDI JRF; NEWELL DR; SMITH IE et al.1983; BRITISH JOURNAL OF CANCER; ISSN 0007-0920; GBR; DA. 1983; VOL. 47; NO 1; PP. 27-33; ABS. ENG; BIBL. 26 REF.; GRAPHArticle

A PHASE I AND CLINICAL PHARMACOLOGY STUDY OF INTRAVENOUSLY ADMINISTERED CARMINOMYCIN IN CANCER PATIENTS IN THE UNITED STATESCOMIS RL; ISSELL BF; PITTMAN K et al.1982; CANCER RES.; ISSN 0008-5472; USA; DA. 1982; VOL. 42; NO 7; PP. 2944-2948; BIBL. 15 REF.Article

Targeted therapy-induced radiation recallLEVY, Antonin; HOLLEBECQUE, Antoine; DEUTSCH, Eric et al.European journal of cancer (1990). 2013, Vol 49, Num 7, pp 1662-1668, issn 0959-8049, 7 p.Article

A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: Unplanned admissions as an early indicator of patient attritionBRUNETTO, Andre T; JOO ERN ANG; JUDSON, Ian et al.European journal of cancer (1990). 2010, Vol 46, Num 15, pp 2739-2745, issn 0959-8049, 7 p.Article

Tolerability and pharmacokinetics of inhaled bimosiamose disodium in healthy malesMEYER, Michael; BEEH, Kai-Michael; BEIER, Jutta et al.British journal of clinical pharmacology. 2007, Vol 63, Num 4, pp 451-458, issn 0306-5251, 8 p.Article

Coherence principles in dose-finding studiesYING KUEN CHEUNG.Biometrika. 2005, Vol 92, Num 4, pp 863-873, issn 0006-3444, 11 p.Article

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?POSTEL-VINAY, S; ARKENAU, H.-T; OLMOS, D et al.British journal of cancer. 2009, Vol 100, Num 9, pp 1373-1378, issn 0007-0920, 6 p.Article

Phase I study of the safety, pharmacokinetics and antitumor activity of famitinibAIPING ZHOU; WEN ZHANG; CHUNXIAO CHANG et al.Cancer chemotherapy and pharmacology. 2013, Vol 72, Num 5, pp 1043-1053, issn 0344-5704, 11 p.Article

Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG)TERRET, C; ZANETTA, S; ROCHE, H et al.European journal of cancer (1990). 2003, Vol 39, Num 8, pp 1097-1104, issn 0959-8049, 8 p.Article

PHASE I TRIAL OF INDICINE-N-OXIDE ON TWO DOSE SCHEDULES = ESSAI PHASE I DE L'INDICINE-N-OXYDE SELON DEUX PROTOCOLES DIFFERENTSTAYLOR S; BELT RJ; HAAS CD et al.1983; CANCER; ISSN 0008-543X; USA; DA. 1983; VOL. 51; NO 11; PP. 1988-1991; ABS. ENG; BIBL. 4 REF.; GRAPHArticle

FINAL REPORT ON THE UNITED STATES PHASE 1 CLINICAL TRIAL OF THE HYPOXIC CELL RADIOSENSITIZER, MISONIDAZOLE (R0-07-0582; NSC#261037)PHILLIPS TL; WASSERMAN TH; JOHNSON RJ et al.1981; CANCER; ISSN 0008-543X; USA; DA. 1981; VOL. 48; NO 8; PP. 1697-1704; BIBL. 15 REF.Article

Bayesian population approaches to the analysis of dose escalation studiesRUSSU, Alberto; DE NICOLAO, Giuseppe; POGGESI, Italo et al.Computer methods and programs in biomedicine (Print). 2012, Vol 107, Num 2, pp 189-201, issn 0169-2607, 13 p.Article

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancerGOETZ, Matthew P; TOFT, David; SALAZAAR, Sandra et al.Journal of clinical oncology. 2005, Vol 23, Num 6, pp 1078-1087, issn 0732-183X, 10 p.Article

Complementary and alternative medicine use by patients enrolled onto phase I clinical trialsDY, Grace K; BEKELE, Lishan; HANSON, Lorelei J et al.Journal of clinical oncology. 2004, Vol 22, Num 23, pp 4758-4763, issn 0732-183X, 6 p.Article